Skip to main content



Moberg Pharma – a different kind of pharma company



A business model with faster time to market and lower development risk compared with conventional drug development



Each year, we evaluate in excess of 100 new business opportunities to identify future bestsellers



We sell Kerasal Nail through 30,000 retail outlets in the U.S

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus. On March 29, 2019, the company divested its OTC Business, see press release

Stockvalue 2013-05-20 14:00
32,90 kr
+2,5 %
Interview with CEO Peter Wolpert
Our global markets


Get our latest press releases and reports


Latest report

2019-04-16 Moberg Pharma Annual Report 2018


Next calendar event: 2019-05-14 Interim report for January - March 2019

Increased sales

Mycological cure rate after MOB-015 treatment